Amyloid precursor protein targeting small interfering RNA - Argo Biopharma
Latest Information Update: 09 Jan 2026
At a glance
- Originator Argo Biopharma
- Class Antidementias; Small interfering RNA
- Mechanism of Action Amyloid beta-protein precursor expression modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Alzheimer's disease
Highest Development Phases
- Research Alzheimer's disease
Most Recent Events
- 10 Dec 2025 Amyloid precursor protein targeting small interfering RNA - Argo Biopharma is available for licensing as of 10 Dec 2025. https://www.argobiopharma.com/partnering/index.html (Argo Biopharma pipeline, December 2025)
- 10 Dec 2025 Early research in Alzheimer's disease in China (Parenteral) (Argo Biopharma pipeline, December 2025)